Ibuprofen, diclofenac, aspirin the peptide has shown protective effects against all of them
In obese, non-diabetic individuals, orforglipron administration for 36 weeks in a phase 2 trial, ranging from 12 mg to 45 mg doses, resulted in dose-dependent weight loss of up to 14.7%, accompanied by improvements in cardiometabolic risk factors [109] (Figure 6)
Peptide decision path Move from research interest to supervised review Direct answer BPC-157 Dosage Guide: Protocols & Safety 2026 should be evaluated through research status, legal access, source quality, safety context, and clinician oversight rather than a shortcut purchase decision
CAS Number: 1401708-83-5
Classified as a growth hormonederived metabolic signaling peptide, AOD 9604 functions as a selective modulator of adipose tissue pathways, enabling targeted investigation of lipolysis without engagement of canonical growth hormone receptor signaling